284 related articles for article (PubMed ID: 34648059)
1. Safety of immune checkpoint inhibitors in non-small-cell lung cancer patients with idiopathic interstitial pneumonia: a matched case-control study.
Ichimura T; Hinata M; Ichikura D; Suzuki S
Cancer Chemother Pharmacol; 2022 Jan; 89(1):21-30. PubMed ID: 34648059
[TBL] [Abstract][Full Text] [Related]
2. Outcome and risk factor of immune-related adverse events and pneumonitis in patients with advanced or postoperative recurrent non-small cell lung cancer treated with immune checkpoint inhibitors.
Isono T; Kagiyama N; Takano K; Hosoda C; Nishida T; Kawate E; Kobayashi Y; Ishiguro T; Takaku Y; Kurashima K; Yanagisawa T; Takayanagi N
Thorac Cancer; 2021 Jan; 12(2):153-164. PubMed ID: 33201587
[TBL] [Abstract][Full Text] [Related]
3. Nivolumab for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia: A multicenter, open-label single-arm phase II trial.
Fujimoto D; Yomota M; Sekine A; Morita M; Morimoto T; Hosomi Y; Ogura T; Tomioka H; Tomii K
Lung Cancer; 2019 Aug; 134():274-278. PubMed ID: 31182249
[TBL] [Abstract][Full Text] [Related]
4. A pilot trial of nivolumab treatment for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia.
Fujimoto D; Morimoto T; Ito J; Sato Y; Ito M; Teraoka S; Otsuka K; Nagata K; Nakagawa A; Tomii K
Lung Cancer; 2017 Sep; 111():1-5. PubMed ID: 28838377
[TBL] [Abstract][Full Text] [Related]
5. Tumor invasion in the central airway is a risk factor for early-onset checkpoint inhibitor pneumonitis in patients with non-small cell lung cancer.
Moda M; Saito H; Kato T; Usui R; Kondo T; Nakahara Y; Murakami S; Yamamoto K; Yamada K
Thorac Cancer; 2020 Dec; 11(12):3576-3584. PubMed ID: 33078531
[TBL] [Abstract][Full Text] [Related]
6. Factors Associated With Efficacy and Nivolumab-Related Interstitial Pneumonia in Non-Small Cell Lung Cancer: A Retrospective Survey.
Hata H; Mio T; Yamashita D; Matsumura C; Chisaki Y; Motohashi H; Yano Y
Cancer Control; 2020; 27(4):1073274820977200. PubMed ID: 33297768
[TBL] [Abstract][Full Text] [Related]
7. Anaplastic lymphoma kinase inhibitor related pneumonitis in patients with non-small cell lung cancer: Clinical and radiologic characteristics and risk factors.
Hwang HJ; Kim MY; Choi CM; Lee JC
Medicine (Baltimore); 2019 Nov; 98(48):e18131. PubMed ID: 31770246
[TBL] [Abstract][Full Text] [Related]
8. Risk of pneumonitis in non-small cell lung cancer patients with preexisting interstitial lung diseases treated with immune checkpoint inhibitors: a nationwide retrospective cohort study.
Sawa K; Sato I; Takeuchi M; Kawakami K
Cancer Immunol Immunother; 2023 Mar; 72(3):591-598. PubMed ID: 35994088
[TBL] [Abstract][Full Text] [Related]
9. Impact of interstitial lung disease associated with immune checkpoint inhibitors on prognosis in patients with non-small-cell lung cancer.
Yamagata A; Yokoyama T; Fukuda Y; Ishida T
Cancer Chemother Pharmacol; 2021 Feb; 87(2):251-258. PubMed ID: 33394102
[TBL] [Abstract][Full Text] [Related]
10. Association of immune-related pneumonitis with clinical benefit of anti-programmed cell death-1 monotherapy in advanced non-small cell lung cancer.
Ono K; Ono H; Toi Y; Sugisaka J; Aso M; Saito R; Kawana S; Aiba T; Odaka T; Matsuda S; Saito S; Narumi A; Ogasawara T; Shimizu H; Domeki Y; Terayama K; Kawashima Y; Nakamura A; Yamanda S; Kimura Y; Honda Y; Sugawara S
Cancer Med; 2021 Jul; 10(14):4796-4804. PubMed ID: 34121358
[TBL] [Abstract][Full Text] [Related]
11. Pre-existing Interstitial Lung Abnormalities and Immune Checkpoint Inhibitor-Related Pneumonitis in Solid Tumors: A Retrospective Analysis.
Horiuchi K; Ikemura S; Sato T; Shimozaki K; Okamori S; Yamada Y; Yokoyama Y; Hashimoto M; Jinzaki M; Hirai I; Funakoshi T; Mizuno R; Oya M; Hirata K; Hamamoto Y; Terai H; Yasuda H; Kawada I; Soejima K; Fukunaga K
Oncologist; 2024 Jan; 29(1):e108-e117. PubMed ID: 37590388
[TBL] [Abstract][Full Text] [Related]
12. Atezolizumab for Pretreated Non-Small Cell Lung Cancer with Idiopathic Interstitial Pneumonia: Final Analysis of Phase II AMBITIOUS Study.
Ikeda S; Kato T; Kenmotsu H; Ogura T; Sato Y; Hino A; Harada T; Kubota K; Tokito T; Okamoto I; Furuya N; Yokoyama T; Hosokawa S; Iwasawa T; Kasajima R; Miyagi Y; Misumi T; Okamoto H
Oncologist; 2022 Sep; 27(9):720-e702. PubMed ID: 35759340
[TBL] [Abstract][Full Text] [Related]
13. Immune checkpoint inhibitor-associated interstitial lung diseases correlate with better prognosis in patients with advanced non-small-cell lung cancer.
Sugano T; Seike M; Saito Y; Kashiwada T; Terasaki Y; Takano N; Hisakane K; Takahashi S; Tanaka T; Takeuchi S; Miyanaga A; Minegishi Y; Noro R; Kubota K; Gemma A
Thorac Cancer; 2020 Apr; 11(4):1052-1060. PubMed ID: 32096610
[TBL] [Abstract][Full Text] [Related]
14. Programmed cell death 1 (PD-1)/PD-ligand 1(PD-L1) inhibitors-related pneumonitis in patients with advanced non-small cell lung cancer.
Sun Y; Shao C; Li S; Xu Y; Xu K; Zhang Y; Huang H; Wang M; Xu Z
Asia Pac J Clin Oncol; 2020 Dec; 16(6):299-304. PubMed ID: 32757454
[TBL] [Abstract][Full Text] [Related]
15. High mortality and poor treatment efficacy of immune checkpoint inhibitors in patients with severe grade checkpoint inhibitor pneumonitis in non-small cell lung cancer.
Tone M; Izumo T; Awano N; Kuse N; Inomata M; Jo T; Yoshimura H; Minami J; Takada K; Miyamoto S; Kunitoh H
Thorac Cancer; 2019 Oct; 10(10):2006-2012. PubMed ID: 31482678
[TBL] [Abstract][Full Text] [Related]
16. Prophylaxis for acute exacerbation of interstitial pneumonia after lung resection.
Ito H; Nakayama H; Yokose T; Yamada K
Asian Cardiovasc Thorac Ann; 2014 Oct; 22(8):948-54. PubMed ID: 24585320
[TBL] [Abstract][Full Text] [Related]
17. Risk Factors for Immune Checkpoint Inhibitor-Related Pneumonitis in Cancer Patients: A Systemic Review and Meta-Analysis.
Zhou P; Zhao X; Wang G
Respiration; 2022; 101(11):1035-1050. PubMed ID: 36108598
[TBL] [Abstract][Full Text] [Related]
18. Are immune checkpoint inhibitors safe and effective in lung cancer patients with pre-existing interstitial lung disease?
Zhu L; Gao R; Li H; Zheng Y; Yang J
Immunotherapy; 2024 Apr; 16(7):465-480. PubMed ID: 38511241
[TBL] [Abstract][Full Text] [Related]
19. Pneumonitis associated with immune checkpoint inhibitors among patients with non-small cell lung cancer.
Shannon VR
Curr Opin Pulm Med; 2020 Jul; 26(4):326-340. PubMed ID: 32452900
[TBL] [Abstract][Full Text] [Related]
20. Weekly paclitaxel in combination with carboplatin for advanced non-small-cell lung cancer complicated by idiopathic interstitial pneumonias: a single-arm phase II study.
Fukuizumi A; Minegishi Y; Omori M; Atsumi K; Takano N; Hisakane K; Takahashi S; Kobayashi K; Sugano T; Takeuchi S; Noro R; Seike M; Kubota K; Azuma A; Gemma A
Int J Clin Oncol; 2019 Dec; 24(12):1543-1548. PubMed ID: 31352631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]